Eliminating barriers to personalized medicine: learning from neurofibromatosis type 1.

Abstract excerpt

With the emergence of high-throughput discovery platforms, robust preclinical small-animal models, and efficient clinical trial pipelines, it is becoming possible to envision a time when the treatment of human neurologic diseases will become personalized. The emergence of precision medicine will require the identification of subgroups of patients most likely to respond to specific biologically based therapies....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Learning
• Share to Mutation
• Share to Neurofibromatosis 1